Human antibodies to Ebola virus glycoprotein

Patent metadata

Field	Value
Publication number	US-10829544-B2
Application number	US-201916663261-A
Country	US
Kind code	B2
Filing date	Oct 24, 2019
Priority date	Jan 26, 2015
Publication date	Nov 10, 2020
Grant date	Nov 10, 2020

Abstract

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

First claim

What is claimed is:

1. A method of increasing survival, or the likelihood of survival of a subject suffering from infection with Ebola Virus (EBOV), or a subject exposed to EBOV, or at risk for exposure to, or for acquiring EBOV, the method comprising administering to a subject in need thereof at least one anti-EBOV antibody or antigen-binding fragment thereof, or a pharmaceutical composition comprising at least one anti-EBOV antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within any one of the heavy chain variable region (HCVR) and light chain variable region (LCVR) amino acid sequence pairs selected from the group consisting of SEQ ID NOs: 18/26, 66/74, and 146/154, or a pharmaceutically acceptable composition comprising the at least one antibody or antigen-binding fragment thereof.

2. The method of claim 1 , comprising administering an antibody cocktail comprising a mixture of at least two anti-EBOV antibodies.

3. The method of claim 1 , comprising administering an antibody cocktail comprising a mixture of three anti-EBOV antibodies, wherein the three anti-EBOV antibodies comprise HCVR/LCVR amino acid sequence pairs as set forth in SEQ ID NOs: 18/26, 66/74 and 146/154.

4. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, or an antibody cocktail comprising a mixture of at least two antibodies, is administered prophylactically or therapeutically to the subject in need thereof.

5. The method of claim 1 , wherein the subject in need thereof who is at risk for exposure to, or for acquiring an EBOV infection is selected from the group consisting of an immunocompromised individual, a healthcare worker, a person who is suspected of having been exposed to a person harboring the Ebola virus, a person who comes into physical contact or close physical proximity with an infected individual, a hospital employee, a pharmaceutical researcher, maintenance personnel responsible for cleaning a hospital facility or institution where an Ebola patient has been treated, individuals who have visited or are planning to visit an area or country known to have or suspected to have an outbreak of Ebola virus and a frequent flyer.

6. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, or the antibody cocktail is administered in combination with a second therapeutic agent.

7. The method of claim 6 , wherein the second therapeutic agent is selected from the group consisting of an anti-viral drug, an anti-inflammatory drug, a different antibody to EBOV, a vaccine for EBOV, small interfering RNAs that target viral RNA polymerase, brincidofovir, favipiravir antisense phosphorodiamidate morpholino oligomers that target Ebola virus VP24 gene, and interferons.

8. The method of claim 1 , wherein the pharmaceutical composition is administered subcutaneously, intravenously, intradermally, intramuscularly, intranasally, or orally.

9. The method of claim 1 , wherein the composition comprises an antibody having the HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 20/22/24/28/30/32, respectively.

10. The method of claim 1 , where the composition comprises an antibody having the HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 68/70/72/76/78/80, respectively.

11. The method of claim 1 , wherein the composition comprises an antibody having the HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 148/150/152/156/158/160, respectively.

12. The method of claim 1 , wherein the composition comprises at least three antibodies, and wherein the antibodies comprise the HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sequence combination of SEQ ID NOs: 20/22/24/28/30/32, 68/70/7 2 / 7 6/78/80, and 148/150/152/156/158/160, respectively.

13. The method of claim 6 , wherein the second therapeutic agent is an anti-inflammatory selected from corticosteroids and non-steroidal anti-inflammatory drugs.

14. The method of claim 6 , wherein the second therapeutic agent is selected from the group consisting of TKM Ebola, CMX-001, T-705, BCX-4430, and AVI-7537.

15. The method of claim 1 , wherein the subject is one for whom a vaccine is contra-indicated, or for whom a vaccine is less efficacious.

16. The method of claim 1 , wherein the subject is elderly or very young.

17. The method of claim 1 , wherein the subject is free of infection or has reduced or no viral titers at the time of administration of the antibody or antigen-binding fragment thereof.

18. The method of claim 1 , wherein the subject is exposed to EBOV by physical contact or close physical proximity with an infected individual.

19. The method of claim 1 , wherein the subject is a hospital worker in an area or country known to have or suspected to have an outbreak of EBOV.

20. The method of claim 1 , wherein the EBOV is a Zaire strain.

Assignees

• Regeneron Pharma

Inventors

• Kyratsous Christos
• Olson William
• Mason Peter
• Stahl Neil

Classifications

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title